Android app on Google Play

ACADIA Pharmaceuticals (ACAD) Sees Early Action on Partner Deal

January 23, 2013 9:25 AM EST Send to a Friend
Get Alerts ACAD Hot Sheet
Trade ACAD Now!
Join SI Premium – FREE
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is on the move early Wednesday which could be related to Allergan, Inc. (NYSE: AGN) deal to acquire MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) for $25 per share, or a 60% premium.

Like MAPP, ACADIA is in a collaboration with Allergan.

Shares last traded at $5.96, up 5%.




You May Also Be Interested In


Related Categories

Rumors, Trader Talk

Add Your Comment